MDMA: device tax will especially harm small companies; Philips Healthcare turns to India;

 @FierceMedDev: Renal denervation's not just for hypertension--docs say it could help diabetics, too. More | Follow @FierceMedDev

 @MarkHFierce: Ilex will sell Novartis' blood test Dx kits in 16 African countries. More | Follow @MarkHFierce

 @DamianFierce: According to a new study, women fare worse with stents than men. More | Follow @DamianFierce

> The impending medical device tax will be especially damaging to small, emerging companies whose profit margins can't sustain a 2.3% hit, according to the Medical Device Manufacturers Association. Story

> Medtronic ($MDT) is launching its Amphirion Plus percutaneous transluminal angioplasty catheter, aimed to relieve narrowing and blockage in below-the-knee arteries. Item

> Tactile Systems Technology, the Minnesota maker of a home lymphedema treatment device, pulled in $10.4 million in a Series B round of financing, MedCity News reports. Story

> Arrayit Diagnostics, maker of molecular cancer tests, pulled in $8 million in financing from the American Equity Fund. News

> Johnson & Johnson's ($JNJ) stock price could soar even higher based on the growth of its medical devices and pharma pipelines, an analyst writes in Forbes. Opinion

> California's Biolase got 510(k) clearance and a CE mark for its Epic 10 dental laser, designed to reduce patient pain in oral surgery. Article

> Cook Medical has launched the Zilver Vena self-expanding stent in Canada. The device is aimed to restore blood flow in obstructed iliofemoral veins. Release

> Philadelphia life sciences startup CytoVas will begin to test a new diagnostic to measure vascular health. Item

> Philips Healthcare ($PHG) is expanding its Indian marketing operations, looking to sell lower-cost devices to hospitals in need. More

Biotech News

 @FierceBiotech: Sanofi stands up for diabetes therapy in crowded GLP-1 contest. More | Follow @FierceBiotech

 @JohnCFierce: Anacor gets an antibiotic back from Glaxo after microbiological resistance was seen in a study. Worthless now. More | Follow @JohnCFierce

 @RyanMFierce: Takeda builds up new vaccine unit with $60M LigoCyte buyout, with interview quotes. Article | Follow @RyanMFierce

> Defining 'fierce' in the modern age of drug and device development. Editor's Corner

> The Medicines Co. abandons blood-loss drug over safety risk. More

Pharma News

@FiercePharma: Takeda continues buying spree, picks up LigoCyte. More | Follow @FiercePharma

@EricPFierce: Australia Mayne Pharma buying SC-based CDMO Metrics for $105 million plus milestone. More | Follow @EricPFierce

> J&J settles Risperdal cases, avoiding former FDA commish's testimony. Story

> NICE reverses position on new use for Novartis' Lucentis. More


Suggested Articles

The drug that treats atrial fibrillation, flecainide, has been around since the '80s. Grace Colón, CEO of InCarda, thinks it needs a face-lift.

3M, maker of the ubiquitous Littmann stethoscope brand, has teamed up with Eko to create a new digital version that amplifies sounds and adds AI.

Study data from Medtronic showed more patients reported improvements in their chronic back pain after treatments with the devicemaker’s tiny implant.